Overview

A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects

Status:
Completed

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

This study is a Phase 1, randomized, double-blind, placebo-controlled study of multiple doses of SAGE-718 using ketamine challenge to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Sage Therapeutics

Treatments:

Ketamine